4.7 Review

Systematic review: the quality of the scientific evidence and conflicts of interest in international inflammatory bowel disease practice guidelines

Journal

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 37, Issue 10, Pages 937-946

Publisher

WILEY
DOI: 10.1111/apt.12290

Keywords

-

Funding

  1. Pfizer
  2. Prometheus diagnostics
  3. Alba Pharmaceuticals
  4. Alvine Therapeutics
  5. Shire Therapeutics

Ask authors/readers for more resources

Background Guidelines published by the international gastroenterology societies establish standards of care and seek to improve patient outcomes. Aim We examined inflammatory bowel disease guidelines (IBD) for quality of evidence, methods of grading evidence and conflicts of interest (COI). Methods All 182 guidelines published by the American College of Gastroenterology, American Gastroenterological Association, British Society of Gastroenterology, Canadian Association of Gastroenterology, Crohn's and Colitis Foundation of America and European Crohn's and Colitis Organisation as of 27 September 2012 were reviewed. Nineteen IBD guidelines were found. Results Eighty-nine per cent (n=17/19) of the guidelines graded the levels of evidence using seven different systems. Of the 1070 recommendations reviewed, 23% (n=249) cited level A evidence; 28% (n=302) level B; 36% (n=383) level C and 13% (n=136) level D. The mean age of the guidelines was 4.2years. In addition, 61% (n=11/19) of the guidelines failed to comment on COI. All eight articles commenting on COI had conflicts with 81% (n=92/113) of authors reported an average 11.7 COI. Lastly, there were variations in the recommendations between societies. Conclusions Nearly half the IBD guideline recommendations are based on expert opinion or no evidence. Majority of the guidelines fail to disclose any COI, and when commenting, all have numerous COI. Furthermore, the guidelines are not updated frequently and there is a lack of consensus between societal guidelines. This study highlights the critical need to centralize and redesign the guidelines development process.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Gastroenterology & Hepatology

Meta-analysis comparing the efficacy and adverse events of biologics and thiopurines for Crohn's Disease after surgery for ulcerative colitis

Abhijeet Yadav, Satya Kurada, Joshua Foromera, Kenneth R. Falchuk, Joseph D. Feuerstein

DIGESTIVE AND LIVER DISEASE (2018)

Letter Gastroenterology & Hepatology

Letter: inflammatory bowel disease guidelines and conflicts of interest - authors' reply

J. D. Feuerstein, D. A. Leffler, A. S. Cheifetz

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)

Letter Gastroenterology & Hepatology

Letter: international IBD practice guidelines Reply

J. D. Feuerstein, D. A. Leffler, A. S. Cheifetz

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)

Letter Medicine, General & Internal

Colonoscopy and Polyp Characteristics

Joseph D. Feuerstein, Daniel A. Leffler

ANNALS OF INTERNAL MEDICINE (2013)

Article Endocrinology & Metabolism

Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells

Daniel Prabakaran, Baogui Wang, Joseph D. Feuerstein, Jennifer A. Sinclair, Priti Bijpuria, Lisa I. Jepeal, M. Michael Wolfe

REGULATORY PEPTIDES (2010)

Editorial Material Gastroenterology & Hepatology

Comparative effectiveness research in inflammatory bowel disease: prospects and challenges

Joseph D. Feuerstein, Adam S. Cheifetz, Corey A. Siegel

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2012)

Editorial Material Gastroenterology & Hepatology

Editorial: older patients are significantly more likely to have colon ischaemia-associated conditions that are chronic and complex

William T. Clarke, Joseph D. Feuerstein

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)

Review Medicine, General & Internal

Ulcerative Colitis

Joseph D. Feuerstein, Alan C. Moss, Francis A. Farraye

MAYO CLINIC PROCEEDINGS (2019)

Article Gastroenterology & Hepatology

Improving All-Cause Inpatient Mortality After Percutaneous Endoscopic Gastrostomy

Daniel J. Stein, Matthew B. Moore, Gila Hoffman, Joseph D. Feuerstein

Summary: Over the past decade, the mortality rate for patients undergoing PEG placement has decreased by approximately 40% without a decrease in complication rates, indicating a potential improvement in patient selection. Despite similar patient characteristics, this trend suggests a positive outcome in terms of patient outcomes.

DIGESTIVE DISEASES AND SCIENCES (2021)

Article Gastroenterology & Hepatology

Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study

Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein

Summary: This study aimed to compare the effect of vedolizumab and anti-TNF therapy on perioperative complications in IBD patients undergoing surgery. The results showed a lower leak rate in the vedolizumab group, and that vedolizumab does not increase perioperative complication rates in IBD surgery when compared to anti-TNF medications.

INTESTINAL RESEARCH (2022)

Review Gastroenterology & Hepatology

Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis

Vikas Taneja, Rajsavi S. Anand, Mohammed El-Dallal, Jeffrey Dong, Nisa Desai, Isha Taneja, Joseph D. Feuerstein

Summary: Patients with inflammatory bowel disease (IBD) who have undergone solid organ transplant can safely use biologic and small molecule therapy for their IBD treatment. The rates of infections associated with these treatments are similar to those of patients without IBD who have received solid organ transplant.

INFLAMMATORY BOWEL DISEASES (2023)

Letter Medicine, General & Internal

Rectal Examination May Not be Necessary in Gastrointestinal Bleeding

Joseph D. Feuerstein

AMERICAN JOURNAL OF MEDICINE (2017)

Letter Medicine, General & Internal

How Physicians Interpret Research Funding Disclosures

Joseph D. Feuerstein, Daniel A. Leffler, Adam S. Cheifetz

NEW ENGLAND JOURNAL OF MEDICINE (2012)

No Data Available